Back to results
CompletedPhase 3

GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy

NCT00688701

What is this trial?

Generating plain-language summary...

Am I eligible?

Generating eligibility summary...

What's involved?

Summarizing study design...

Where and how to apply

Primary location

Sanofi-Aventis Administrative Office

Bridgewater, New Jersey, United States

+11 additional locations

View on ClinicalTrials.gov
GLP-1 Receptor Agonist Lixisenatide in Patients With Type 2 Diabetes for Glycemic Control and Safety Evaluation in Monotherapy — TrialFind